| Literature DB >> 26187875 |
Lyn S Chitty1, Y M Dennis Lo2.
Abstract
The identification of cell-free fetal DNA (cffDNA) in maternal plasma in 1997 heralded the most significant change in obstetric care for decades, with the advent of safer screening and diagnosis based on analysis of maternal blood. Here, we describe how the technological advances offered by next-generation sequencing have allowed for the development of a highly sensitive screening test for aneuploidies as well as definitive prenatal molecular diagnosis for some monogenic disorders.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26187875 PMCID: PMC4561399 DOI: 10.1101/cshperspect.a023085
Source DB: PubMed Journal: Cold Spring Harb Perspect Med ISSN: 2157-1422 Impact factor: 6.915